INHIBITORS OF BRUTON'S TYROSINE KINASE

1 .- 100 . (canceled)

101 . A method for treating mastocytosis in an individual comprising administering to the individual a compound having the structure of Formula (A1):

wherein

A is N;

R 1 is L 2 -(substituted or unsubstituted aryl), where L 2 is a bond, O, S, —S(═O), —S(═O) 2 , C(═O), -(substituted or unsubstituted C 1 -C 6 alkyl), or -(substituted or unsubstituted C 2 -C 6 alkenyl);

R 2 and R 3 are independently selected from H, lower alkyl and substituted lower alkyl;

R 4 is L 3 -X-L 4 -G, wherein,

L 3 is optional, and when present is a bond, or an optionally substituted group selected from alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, or alkylheterocycloalkyl;

X is optional, and when present is a bond, O, —C(═O), S, —S(═O), —S(═O) 2 , —NH, —NR 9 , —NHC(O), —C(O)NH, —NR 9 C(O), —C(O)NR 9 , —S(═O) 2 NH, —NHS(═O) 2 , —S(═O) 2 NR 9 —, —NR 9 S(═O) 2 , —OC(O)NH—, —NHC(O)O—, —OC(O)NR 9 —, —NR 9 C(O)O—, —CH═NO—, —ON═CH—, —NR 10 C(O)NR 10 —, heteroaryl, aryl, —NR 10 C(═NR 11 )NR 10 —, —NR 10 C(═NR 11 )—, —C(═NR 11 )NR 10 —, —OC(═NR 11 )—, or —C(═NR 11 )O—;

L 4 is optional, and when present is a bond, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle;

or L 3 , X and L 4 taken together form a nitrogen containing heterocyclic ring, or an optionally substituted group selected from alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, or alkylheterocycloalkyl;

G is

where R a is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl; and either

R 7 and R 8 are H; and R 6 is H; or

R 7 and R 8 taken together form a bond; and R 6 is H;

each R 9 is independently selected from among H, substituted or unsubstituted lower alkyl, and substituted or unsubstituted lower cycloalkyl;

each R 10 is independently H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower cycloalkyl; or

two R 10 groups can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; or

R 10 and R 11 can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; or

each R 11 is independently selected from H, —S(═O) 2 R 8 , —S(═O) 2 NH 2 , —C(O)R 8 , —CN, —NO 2 , heteroaryl, or heteroalkyl; or a pharmaceutically acceptable salt thereof.

102 . The method of claim 101 wherein the compound has the structure of Formula (B 1):

wherein:

each R a is independently H, -L a -(substituted or unsubstituted heteroaryl), or -L a -(substituted or unsubstituted aryl), wherein L a is a bond, O, S, —S(═O), —S(═O) 2 , NH, C(O), CH 2 , —NHC(O)O, —NHC(O), or —C(O)NH;

G is

where R a is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl; and either

R 7 and R 8 are H; and R 6 is H; or

R 7 and R 8 taken together form a bond; and R 6 is H;

Y and R 12 taken together form a 4-, 5-, or 6-membered heterocyclic ring; or

a pharmaceutically acceptable salt thereof.

103 . The method of claim 101 wherein the compound has the structure of Formula (C1):

wherein Y and R 12 taken together form a 4-, 5-, or 6-membered heterocyclic ring;

G is

where R a is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl; and either

R 7 and R 8 are H; and R 6 is H; or

R 7 and R 8 taken together form a bond; and R 6 is H; or a pharmaceutically acceptable salt thereof.

104 . The method of claim 103 wherein G is

105 . The method of claim 103 wherein R 7 and R 8 are H; and R 6 is H.

106 . A method for treating mastocytosis in an individual comprising administering to the individual a compound having the structure

or a pharmaceutically acceptable salt thereof.

107 . The method of claim 101 or 106 , wherein the compound is administered orally.